Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts. - 2Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- 3The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- 410 Hints for an Effective New employee screening
- 5It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- A Couple of Modest Guitars for 2024
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- How effective is the flu shot this year? New report shows promising results
- Vote in favor of your #1 Kind of Cap
- How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- Americans generally like wolves − except when we’re reminded of our politics
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- Signature Scents: A Manual for Outstanding Fragrances
